 Clarus Therapeutics Holdings Inc NASDAQ: CRXT and Canadas McGill University have announced licensing agreement whereby Clarus will develop and commercialize McGills proprietary technology designed to treat conditions associated with CoQ10 deficiencies. Coenzyme-Q10 Ubiquinone is synthesized in the inner membrane of mitochondria, a cellular organelle whose primary function is to produce the bodys chemical energy. 